Akebia starts Phase 2 trial for rare kidney disease drug ebribafusp

August 3, 2026 8:00 AM

Akebia Therapeutics, Inc. (Nasdaq: AKBA) has initiated a Phase 2 basket trial to evaluate ebribafusp, an investigational complement inhibitor, in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found